secwatch.observer — SEC 8-K summary
======================================

Issuer:     LEXICON PHARMACEUTICALS, INC. (LXRX)
CIK:        0001062822
Form:       8-K
Filed at:   2024-07-08T23:59:59+00:00
Accession:  0001062822-24-000036
Event type: leadership
Sentiment:  neutral
Materiality: 0.75
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Lexicon appoints Michael Exton as CEO effective July 8, 2024; Jeffrey Wade promoted to President and COO
--------------------------------------------------------------------------------

- New CEO Michael Exton, Ph.D., former Novartis cardiometabolism head, to lead Lexicon starting July 8, 2024.
- Exton receives $636k base salary, 70% bonus target, and stock option for 1,675,000 shares vesting over 4 years.
- Jeffrey Wade promoted from President/CFO to President/COO; base salary increased to $585k, bonus target to 60%.
- Wade granted stock option for 307,000 shares vesting over 4 years; also remains principal financial officer.
- Severance for Exton: 12 months salary on termination w/o cause; additional one-time bonus target on change of control.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1062822/000106282224000036/0001062822-24-000036-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1062822/000106282224000036/lxrx-20240703.htm
  HTML page:      https://secwatch.observer/filing/0001062822-24-000036

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer